Anthem Biosciences IPO Details
IPO Date	July 14, 2025 to July 16, 2025
Listing Date	July 21, 2025
Face Value	₹2 per share
Issue Price Band	₹540 to ₹570 per share
Issue Price Final	₹570 per share
Lot Size	26 Shares
Sale Type	Offer For Sale
Total Issue Size	5,95,75,319 shares
(aggregating up to ₹3,395.00 Cr)
Employee Discount	₹50.00
Issue Type	Bookbuilding IPO
Listing At	BSE, NSE
Share Holding Pre Issue	56,16,10,051 shares
Share Holding Post Issue	56,16,10,051 shares
Anthem Biosciences IPO Reservation
Anthem Biosciences IPO offers total 5,95,75,319 shares. Out of which 2,97,08,332 (49.87%) allocated to QIB, 1,18,83,333 (19.95%) allocated to QIB (Ex- Anchor), 89,12,500 (14.96%) allocated to NII, 2,07,95,834 (34.91%) allocated to RII and 1,78,24,999 (29.92%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
QIB Shares Offered	2,97,08,332 (49.87%)	NA
NII (HNI) Shares Offered	89,12,500 (14.96%)	NA
Retail Shares Offered	2,07,95,834 (34.91%)	7,99,839
Employee Shares Offered	1,58,653 (0.27%)	NA
Total Shares Offered	5,95,75,319 (100.00%)	
Investor Category Reservations
Application Category	Maximum Bidding Limits	Bidding at Cut-off Price Allowed
Only RII	Up to Rs 2 Lakhs	Yes
Only sNII	Rs 2 Lakhs to Rs 10 Lakhs	No
Only bNII	Rs 10 Lakhs to NII Reservation Portion	No
Only employee		Yes
Employee + RII/NII	
Employee limit: (In certain cases, employees are given discount if bidding amount is upto Rs. 2 lakhs)
If applying as RII: Upto Rs. 2 lakhs
If applying as NII: sNII > Rs. 2 lakhs and upto Rs. 10 lakhs and bNII > Rs. 10 lakhs
Yes for Employee and RII/NII
Anthem Biosciences IPO Anchor Investors Details
Anthem Biosciences IPO raises ₹1,016.02 crore from anchor investors. Anthem Biosciences IPO Anchor bid date is July 11, 2025. Anthem Biosciences IPO Anchor Investors list

Bid Date	July 11, 2025
Shares Offered	1,78,24,999
Anchor Portion Size (In Cr.)	1,016.02
Anchor lock-in period end date for 50% shares (30 Days)	August 15, 2025
Anchor lock-in period end date for remaining shares (90 Days)	October 14, 2025
Anthem Biosciences IPO Timeline (Tentative Schedule)
Anthem Biosciences IPO opens on July 14, 2025, and closes on July 16, 2025.

IPO Open Date	Mon, Jul 14, 2025
IPO Close Date	Wed, Jul 16, 2025
Tentative Allotment	Thu, Jul 17, 2025
Initiation of Refunds	Fri, Jul 18, 2025
Credit of Shares to Demat	Fri, Jul 18, 2025
Tentative Listing Date	Mon, Jul 21, 2025
Cut-off time for UPI mandate confirmation	5 PM on Wed, Jul 16, 2025
Anthem Biosciences IPO Lot Size
Investors can bid for a minimum of 26 shares and in multiples thereof.  The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (Min)	1	26	₹14,820
Retail (Max)	13	338	₹1,92,660
S-HNI (Min)	14	364	₹2,07,480
S-HNI (Max)	67	1,742	₹9,92,940
B-HNI (Min)	68	1,768	₹10,07,760
Anthem Biosciences IPO Promoter Holding
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.
Promoter Holding Pre Issue	76.87%
Promoter Holding Post Issue	74.68%
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue

About Anthem Biosciences Ltd.
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.

The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.

The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.

As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).

As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.

As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.

As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.

As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.

Competitive Strength

One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.
Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
Long-standing relationships with a large, diversified and loyal customer base.
Professional and experienced leadership team supported by a qualified scientific talent pool.
Company Financials
Anthem Biosciences Ltd. Financial Information (Restated)
Anthem Biosciences Ltd.'s revenue increased by 30% and profit after tax (PAT) rose by 23% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	2,807.58	2,398.11	2,014.46
Total Income	1,930.29	1,483.07	1,133.99
Profit After Tax	451.26	367.31	385.19
EBITDA	683.78	519.96	446.05
Net Worth	2,409.86	1,924.66	1,740.67
Reserves and Surplus	2,298.05	1,815.39	1,628.88
Total Borrowing	108.95	232.53	125.06
Amount in ₹ Crore
Key Performance Indicator (KPI)
The market capitalization of Anthem Biosciences IPO is ₹31867.39 Cr.

KPI as of Mon, Mar 31, 2025.

KPI	Values
ROE	20.82%
ROCE	26.88%
Debt/Equity	0.05
RoNW	20.82%
PAT Margin	23.38%
EBITDA Margin	36.81%
Price to Book Value	13.23
Check Anthem Biosciences IPO Peer Comparison here.
Pre IPO	Post IPO
EPS Rs	8.07	8.07
P/E (x)	70.62	70.62
Note:
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2025 that is available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2025 that is available in RHP.
Objects of the Issue (Anthem Biosciences IPO Objectives)
The Company Anthem Biosciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

S.No.	Objects of the Issue	Expected Amount (₹ in crores)
1	To achieve the benefits of listing the Equity Shares on the Stock Exchanges	
Anthem Biosciences IPO Review
[Dilip Davda]  ABL is one of the leading global players in innovation driven, technology focused CRDMO segment. It enjoys niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods. Higher net for FY23 is attributed to exceptional income adjustment for the said year. Though prima-facie the issue appears aggressively priced, investors may park funds for long term. Read detail review...

Anthem Biosciences IPO Subscription Status (Bidding Detail)
The Anthem Biosciences IPO is subscribed 67.42 times on July 16, 2025 4:59:33 PM (Day 3). The public issue subscribed 5.98 times in the retail category, 192.80 times in the QIB category, and 44.70 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (times)	Shares Offered	Shares bid for
QIB	192.80	1,18,83,334	2,29,10,95,976
NII	44.70	89,12,500	39,84,26,912
    bNII (bids above ₹10L)	51.66	59,41,667	30,69,18,534
    sNII (bids below ₹10L)	30.80	29,70,833	9,15,08,378
Retail	5.98	2,07,95,833	12,42,99,214
Employee	6.99	1,58,654	11,08,692
Total	67.42	4,17,50,321	2,81,49,30,794
Total Application : 37,94,038

Anthem Biosciences IPO Prospectus
  ›  Anthem Biosciences IPO DRHP
  ›  Anthem Biosciences IPO RHP
  ›  Anchor Investors in Anthem Biosciences IPO
  ›  Anthem Biosciences IPO Final Prospectus
Anthem Biosciences IPO Listing Details
Listing Date	July 21, 2025
BSE Script Code	544449
NSE Symbol	ANTHEM
ISIN	INE0CZ201020
Final Issue Price	₹570 per share
NSE Listing Group	EQ (Rolling)
BSE Listing Group	B (Rolling)
Pre-Open Session - NSEPre-Open Session - BSE

Listing Day Trading Information
Price Details	NSE SME	NSE SME
Final Issue Price	₹570.00	₹570.00
Open	₹723.10	₹723.05
Low	₹723.05	₹723.05
High	₹746.70	₹747.00
Last Trade	₹730.35	₹730.35